AZENTA INC (AZTA) Stock Fundamental Analysis

NASDAQ:AZTA • US1143401024

28.62 USD
+0.5 (+1.78%)
At close: Feb 13, 2026
28.62 USD
0 (0%)
After Hours: 2/13/2026, 8:00:01 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to AZTA. AZTA was compared to 58 industry peers in the Life Sciences Tools & Services industry. AZTA has a great financial health rating, but its profitability evaluates not so good. AZTA has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • AZTA had positive earnings in the past year.
  • In the past year AZTA had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: AZTA reported negative net income in multiple years.
  • AZTA had a positive operating cash flow in 4 of the past 5 years.
AZTA Yearly Net Income VS EBIT VS OCF VS FCFAZTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B 2B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -2.79%, AZTA is in line with its industry, outperforming 55.17% of the companies in the same industry.
  • With a Return On Equity value of -3.37%, AZTA perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
Industry RankSector Rank
ROA -2.79%
ROE -3.37%
ROIC N/A
ROA(3y)-3.69%
ROA(5y)10.48%
ROE(3y)-4.38%
ROE(5y)11.73%
ROIC(3y)N/A
ROIC(5y)N/A
AZTA Yearly ROA, ROE, ROICAZTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

1.3 Margins

  • AZTA has a Gross Margin of 44.59%. This is comparable to the rest of the industry: AZTA outperforms 43.10% of its industry peers.
  • In the last couple of years the Gross Margin of AZTA has remained more or less at the same level.
  • AZTA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y0.54%
AZTA Yearly Profit, Operating, Gross MarginsAZTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 200 300

8

2. Health

2.1 Basic Checks

  • AZTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AZTA has more shares outstanding
  • The number of shares outstanding for AZTA has been reduced compared to 5 years ago.
  • The debt/assets ratio for AZTA has been reduced compared to a year ago.
AZTA Yearly Shares OutstandingAZTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
AZTA Yearly Total Debt VS Total AssetsAZTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 3.67 indicates that AZTA is not in any danger for bankruptcy at the moment.
  • AZTA's Altman-Z score of 3.67 is fine compared to the rest of the industry. AZTA outperforms 75.86% of its industry peers.
  • AZTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.67
ROIC/WACCN/A
WACC10.82%
AZTA Yearly LT Debt VS Equity VS FCFAZTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 2.92 indicates that AZTA has no problem at all paying its short term obligations.
  • AZTA has a Current ratio of 2.92. This is comparable to the rest of the industry: AZTA outperforms 51.72% of its industry peers.
  • AZTA has a Quick Ratio of 2.61. This indicates that AZTA is financially healthy and has no problem in meeting its short term obligations.
  • AZTA's Quick ratio of 2.61 is in line compared to the rest of the industry. AZTA outperforms 53.45% of its industry peers.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.61
AZTA Yearly Current Assets VS Current LiabilitesAZTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

5

3. Growth

3.1 Past

  • AZTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.89%, which is quite good.
  • Measured over the past years, AZTA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -16.04% on average per year.
  • The Revenue has decreased by -8.40% in the past year.
  • Measured over the past years, AZTA shows a quite strong growth in Revenue. The Revenue has been growing by 8.86% on average per year.
EPS 1Y (TTM)14.89%
EPS 3Y0.64%
EPS 5Y-16.04%
EPS Q2Q%12.5%
Revenue 1Y (TTM)-8.4%
Revenue growth 3Y2.25%
Revenue growth 5Y8.86%
Sales Q2Q%0.77%

3.2 Future

  • Based on estimates for the next years, AZTA will show a very strong growth in Earnings Per Share. The EPS will grow by 27.49% on average per year.
  • The Revenue is expected to grow by 5.37% on average over the next years.
EPS Next Y51.12%
EPS Next 2Y39.62%
EPS Next 3Y33.99%
EPS Next 5Y27.49%
Revenue Next Year4.59%
Revenue Next 2Y4.91%
Revenue Next 3Y5.2%
Revenue Next 5Y5.37%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AZTA Yearly Revenue VS EstimatesAZTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
AZTA Yearly EPS VS EstimatesAZTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2 2.5

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 53.00, AZTA can be considered very expensive at the moment.
  • AZTA's Price/Earnings is on the same level as the industry average.
  • When comparing the Price/Earnings ratio of AZTA to the average of the S&P500 Index (27.97), we can say AZTA is valued expensively.
  • With a Price/Forward Earnings ratio of 27.70, AZTA can be considered very expensive at the moment.
  • 67.24% of the companies in the same industry are more expensive than AZTA, based on the Price/Forward Earnings ratio.
  • AZTA's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.96.
Industry RankSector Rank
PE 53
Fwd PE 27.7
AZTA Price Earnings VS Forward Price EarningsAZTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AZTA indicates a somewhat cheap valuation: AZTA is cheaper than 65.52% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of AZTA indicates a somewhat cheap valuation: AZTA is cheaper than 63.79% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 42.62
EV/EBITDA 20.36
AZTA Per share dataAZTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • AZTA's earnings are expected to grow with 33.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.04
PEG (5Y)N/A
EPS Next 2Y39.62%
EPS Next 3Y33.99%

0

5. Dividend

5.1 Amount

  • AZTA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

AZENTA INC

NASDAQ:AZTA (2/13/2026, 8:00:01 PM)

After market: 28.62 0 (0%)

28.62

+0.5 (+1.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-04
Earnings (Next)05-05
Inst Owners111.91%
Inst Owner ChangeN/A
Ins Owners0.63%
Ins Owner Change12.39%
Market Cap1.32B
Revenue(TTM)594.95M
Net Income(TTM)-57.85M
Analysts75.71
Price Target40.22 (40.53%)
Short Float %9.08%
Short Ratio5.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.65%
Min EPS beat(2)-35.95%
Max EPS beat(2)8.65%
EPS beat(4)2
Avg EPS beat(4)-5.26%
Min EPS beat(4)-35.95%
Max EPS beat(4)36.22%
EPS beat(8)6
Avg EPS beat(8)46.66%
EPS beat(12)9
Avg EPS beat(12)140.12%
EPS beat(16)13
Avg EPS beat(16)118.13%
Revenue beat(2)0
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-0.98%
Max Revenue beat(2)-0.05%
Revenue beat(4)0
Avg Revenue beat(4)-1.7%
Min Revenue beat(4)-5.56%
Max Revenue beat(4)-0.05%
Revenue beat(8)1
Avg Revenue beat(8)-1.26%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)6
Avg Revenue beat(16)-1.08%
PT rev (1m)1.47%
PT rev (3m)22.67%
EPS NQ rev (1m)1.29%
EPS NQ rev (3m)-19.13%
EPS NY rev (1m)0.27%
EPS NY rev (3m)1.47%
Revenue NQ rev (1m)-0.27%
Revenue NQ rev (3m)-3.58%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.43%
Valuation
Industry RankSector Rank
PE 53
Fwd PE 27.7
P/S 2.22
P/FCF 42.62
P/OCF 21.13
P/B 0.77
P/tB 1.44
EV/EBITDA 20.36
EPS(TTM)0.54
EY1.89%
EPS(NY)1.03
Fwd EY3.61%
FCF(TTM)0.67
FCFY2.35%
OCF(TTM)1.35
OCFY4.73%
SpS12.92
BVpS37.23
TBVpS19.88
PEG (NY)1.04
PEG (5Y)N/A
Graham Number21.27
Profitability
Industry RankSector Rank
ROA -2.79%
ROE -3.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.59%
FCFM 5.2%
ROA(3y)-3.69%
ROA(5y)10.48%
ROE(3y)-4.38%
ROE(5y)11.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y0.54%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 55.45%
Cap/Sales 5.29%
Interest Coverage N/A
Cash Conversion 156.34%
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.61
Altman-Z 3.67
F-Score5
WACC10.82%
ROIC/WACCN/A
Cap/Depr(3y)47.53%
Cap/Depr(5y)73.52%
Cap/Sales(3y)6.46%
Cap/Sales(5y)8.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.89%
EPS 3Y0.64%
EPS 5Y-16.04%
EPS Q2Q%12.5%
EPS Next Y51.12%
EPS Next 2Y39.62%
EPS Next 3Y33.99%
EPS Next 5Y27.49%
Revenue 1Y (TTM)-8.4%
Revenue growth 3Y2.25%
Revenue growth 5Y8.86%
Sales Q2Q%0.77%
Revenue Next Year4.59%
Revenue Next 2Y4.91%
Revenue Next 3Y5.2%
Revenue Next 5Y5.37%
EBIT growth 1Y71.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year516.37%
EBIT Next 3Y105.69%
EBIT Next 5YN/A
FCF growth 1Y-4.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.01%
OCF growth 3YN/A
OCF growth 5Y13.75%

AZENTA INC / AZTA FAQ

Can you provide the ChartMill fundamental rating for AZENTA INC?

ChartMill assigns a fundamental rating of 5 / 10 to AZTA.


What is the valuation status of AZENTA INC (AZTA) stock?

ChartMill assigns a valuation rating of 4 / 10 to AZENTA INC (AZTA). This can be considered as Fairly Valued.


How profitable is AZENTA INC (AZTA) stock?

AZENTA INC (AZTA) has a profitability rating of 2 / 10.


Can you provide the financial health for AZTA stock?

The financial health rating of AZENTA INC (AZTA) is 8 / 10.


How sustainable is the dividend of AZENTA INC (AZTA) stock?

The dividend rating of AZENTA INC (AZTA) is 0 / 10 and the dividend payout ratio is 0%.